Similar articles

Abstract: Objective: Acute pulmonary thromboembolism (PTE) is a serious high mortality pulmonary vascular disease whose effective treatment decreases morbidity and mortality. To determine if low-molecular-weight-heparin (LMWH) is clinically as efficient and safe as unfractionated heparin (UH) in patients with diagnosis of acute non-massive PTE, our study compares the efficacy, adverse effects and costs of LMWH and UH. Methods: One hundred and fourteen patients with non-massive acute PTE were randomly divided into LMWH (nadroparin calcium) and UH groups. Oxygenation index, D-dimer, fibrinogen (FG), lung ventilation/perfusion (V/Q) scan and computed tomography pulmonary angiography (CTPA) were observed before anticoagulation and on day 14 after anticoagulation. Results: In both groups, the ABG (arterial blood gas) analysis showed PaO₂ and PaCO₂ were elevated, P(A-a)O₂ was decreased and oxygenation index (PaO₂/FIO₂) was elevated, D-dimer and fibrinogen were decreased, lung V/Q and CTPA showed embolized segments reduced (P<0.05). Hemorrhage and thrombocytopenia occurred in 3.5% of the LMWH group. Hemorrhage occurred in 5.3% and thrombocytopenia occurred in 7.0% of the UH group. The average cost in the LMWH group was RMB 1218.60 Yuan and RMB 1541.40 Yuan in the UH group. Conclusion: LMWH and UH are equally effective for treatment of non-massive acute PTE, but LMWH may have a lower prevalence of complications and is less expensive.

[1] Buller, H.R., 2002. Treatment of symptomatic venous thromboembolism: improving outcomes. Semin. Thromb. Hemost., 28(Suppl 2):41-48.

[2] Buller, H.R., Agnelli, G., Hull, R.D., Hyers, T.M., Prins, M.H., Raskob, G.E., 2004. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest., 126(3 Suppl):401S-428S.

[3] Chinese Medical Association (Respiratory Branch), 2001. The guideline of diagnosis and treatment of PTE (draft). Chin. J. Tuberc. Respir. Dis., 24(5):273-275 (in Chinese).

[4] Davis, R., Faulds, D., 1997. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging., 10(4):299-322.

[5] Deitcher, S.R., Carman, T.L., 2002. Deep venous thrombosis and pulmonary embolism. Curr. Treat Options Cardiovasc. Med., 4(3):223-238.

[6] Eikelboom, J.W., Hankey, G.J., 2002. Low molecular weight heparins and heparinoids. Med. J. Aust., 177(7):379-383.

[7] Estrada, C.A., Mansfield, C.J., Heudebert, G.R., 2000. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J. Gen. Intern. Med., 15(2):108-115.

[8] Gylys, K.H., 2001. Pharmacology department. J. Cardiovasc. Nurs., 15(4):91-95.

[9] Holzheimer, R.G., 2004. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur. J. Med. Res., 9(4):225-239.

[10] Manganaro, A., Giannino, D., Lembo, D., Bruni, F., Consolo, F., 2000. Evolution in the pharmacological treatment of venous thrombosis according to evidence-based medicine. Minerva Cardioangiol., 48(12 Suppl 1):41-51 (in Italian).

[11] Marbet, G.A., 2003. Heparins. Ther. Umsch., 60(1):10-13 (in German).

[12] McRae, S.J., Ginsberg, J.S., 2004. Initial treatment of venous thromboembolism. Circulation, 110(9 Suppl 1):I3-I9.

[13] Messmore, H.L., Covne, E., Wehrmacher, W.H., Demir, A.M., Fareed, J., 2004. Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review. Curr. Pharm. Des., 10(9):1001-1010.

[14] Moreno-Palomares, J.J., Fisac-Herrero, R.M., Herrero-Domingo, A., Ferreira-Pasos, E.M., Grasa, J., Reverte-Cejudo, D., 2001. Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis. An. Med. Interna., 18(7):364-368 (in Spanish).

[15] Ng, H.J., Lee, L.H., 2003. Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy. Int. J. Hematol., 77(2):185-187.

[16] Nicolaides, A.N., Breddin, H.K., Fareed, J., 2001. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int. Angiol., 20(1):1-37.

[17] Pineo, G.F., Hull, R.D., 1998. Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism. Baillieres. Clin. Haematol., 11(3):621-637.

[18] Valiukiene, L., Naudziunas, A., Unikauskas, A., 2003. Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials). Medicina (Kaunas), 39(4):352-358 (in Lithuanian).

[19] Wells, P.S., 2001. Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism. Curr. Opin. Pulm. Med., 7(5):360-364.

[20] Wells, P.S., Buller, H.R., 2001. Outpatient treatment of patients with pulmonary embolism. Semin. Vasc. Med., 1(2):229-234.